Predicting the Effective Dose of 5-Aminolevulinic Acid to Protect Humans From Renal Ischemia-Reperfusion Injury: A Study in Micro Miniature Pigs

Kiyotaka Fujina, Motoaki Sanoc, Yoshinori Katsumatac, d, Kazuki Sato d, Eiji Kobayashib

Abstract

Background: In rodent models, 5-aminolevulinic acid (5-ALA) was shown to prevent renal ischemia-reperfusion injury, but the data did not allow estimation of the human equivalent dose (HED). Therefore, this study evaluated the renal effects of 5-ALA and estimated the HED in micro miniature pigs, which have a metabolism closer to that of humans.

Methods: We analyzed the efficacy and pharmacokinetics of 5-ALA by administering it to nine micro miniature pigs 2 days before renal ischemia-reperfusion injury. A pathological score was calculated on the basis of renal tissue damage; the blood concentration of 5-ALA required to prevent damage was estimated from the expected pathological score by back-calculating it from the obtained approximate expression. The pharmacokinetics data obtained in phase 1 human trials (5-ALA dose vs. blood concentration curve) were used to calculate the HED.

Results: Dose-dependent improvement in tissue damage (rated as a pathological score) was confirmed 7 days after reperfusion. In each animal, the blood concentrations of 5-ALA correlated with the pathological score. We estimated that doses of approximately 1.6 mg/kg and 13.4 mg/kg would be required to obtain histopathology scores of 4 and 3.7 in humans, respectively.

Conclusions: This is the first study to show that the HED of 5-ALA can be calculated from efficacy and pharmacokinetics data obtained in micro miniature pigs.

Keywords: 5-aminolevulinic acid; Renal ischemia-reperfusion injury; Pathological scoring; Micro miniature pig; Human equivalent dose

Introduction

5-aminolevulinic acid (5-ALA) is a natural amino acid found in the mitochondria that is involved in energy production in all living organisms. It is intracellularly converted into protoporphyrin IX (PPIX), which in animals then forms a complex with iron to create heme, a component of the oxygen carrier hemoglobin.

5-ALA has been introduced into health foods with the aim to achieve beneficial effects in several human diseases related to abnormal energy metabolism [1, 2]; however, the effects of 5-ALA vary depending on its concentration. At low concentrations (2.5 mg/kg), 5-ALA is effective in activating the electron transport system of mitochondria. Extremely high doses of 5-ALA (20 mg/kg) are used for photodynamic therapy, which aims to treat cancer through the accumulation of PPIX after administration of 5-ALA [3]. In rodent models, administration of a high dose of 5-ALA (30 - 100 mg/kg) has been reported to induce heme oxygenase-1, which can prevent renal ischemia-reperfusion injury [4], have anti-inflammatory effects in liver [5] and kidney injuries [6], and induce immune tolerance [7]. Even though 5-ALA has been used *in vivo* in humans and has extremely low toxicity, further tests in animals that are closely related to humans are required to estimate the human equivalent dose (HED) because the results of animal experiments differ depending on the concentration used [8].

5-ALA was previously shown to prevent renal ischemia-reperfusion injury in mouse models. However, micro miniature pigs are better suited for experiments to outline cell therapies and drug usages that can be applied to humans [9]. Furthermore, these pigs are preferable to domestic pigs because their body weight does not exceed 20 kg even in adulthood. Therefore, this study aimed to verify the HED of 5-ALA in micro miniature pigs by using the known pathological changes after renal ischemia-reperfusion injury in these animals as the evaluation points to convert the concentrations of 5-ALA to
the HED. The preventive effects of 5-ALA on renal ischemia-reperfusion injury were pathologically verified with two concentrations. This is the first study to verify the pharmacological effects of 5-ALA products with adequate background as health foods on renal ischemia-reperfusion injury in a micro miniature pig model.

**Materials and Methods**

**Laboratory animals and drugs**

The study used three male and six female 12-month-old mature micro miniature pigs that were born during the same period in the same facility (Fuji Micra Co., Ltd, Shizuoka, Japan). The mean weight of the pigs was 16.2 ± 0.7 kg. The animals were organized into the following three groups (n = 3 in each group (one male and two females)): normal food group (control group), 10 mg/kg 5-ALA administration group (5-ALA-HCl 10 mg/kg + sodium ferrous citrate (SFC) 7.9 mg/kg), and 100 mg/kg 5-ALA administration group (5-ALA-HCl 100 mg/kg + SFC 78.5 mg/kg). The molar ratio of 5-ALA to SFC in both 5-ALA groups was 1:0.25.

The lower dose (10 mg/kg 5-ALA) was converted from the dose in small animals that was found to induce heme oxygenase-1, anti-inflammation, and immune tolerance. The higher dose (100 mg/kg 5-ALA) was based on the concentration used for photodynamic detection or photodynamic therapy [3].

The micro miniature pigs were administered 5-ALA + SFC a total of three times, namely 48, 24, and 2 h (day -2, -1, and 0, respectively) before treatment for renal ischemia-reperfusion injury. 5-ALA was mixed with a small amount of normal food and SFC to form a dumpling. The animals ingested the whole dumpling before breakfast and received normal food thereafter.

![Figure 1](https://example.com)
Ethical issues

The present study was designed according to the principles of the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines [10]. Experiments were performed in accordance with the institutional guidelines and the Japanese law on the protection and management of animals. The full ethical proposal was approved by the Research Council and Animal Care and Use Committee of Keio University (approval no: 12094, 200005). Surgical procedures were performed by a surgeon with experience of more than 200 clinical transplant operations who is a steering member of the transplantation society and a permanent director of the transplantation society of Japan (EK).

Treatment for renal ischemia-reperfusion injury

Surgical renal ischemia was performed in the micro miniature pigs by a simplified version of the previously described method [11, 12]. The pigs were fasted for 12 h before the procedure, with free access to water. An intramuscular injection of xylazine hydrochloride was given 15 min before the induction of isoflurane anesthesia to immobilize the animals. Laparotomy was performed by making a midline incision on the abdomen. The left kidney was exposed, and Gerota’s fascia was stripped from the left outer side so that the renal arteries and veins were visible (Fig. 1a, b). After adding 1 mL (1,000 units) of heparin to this area, a vascular clip was applied to the left renal arteries and veins to induce warm ischemia of the left kidney (Fig. 1c). Then, the roots of the right renal arteries and veins were ligated with 1-0 silk, the right ureter was ligated, and the right kidney was removed. One hour after induction of ischemia, the clip on the left kidney was removed, blood reperfusion was confirmed (Fig. 1d), and the abdomen was closed.

Postoperative management and blood sampling

An antibiotic (100 mg/kg body weight of kanamycin intramuscular (IM)) was administered once during the operation, and each animal was kept in an individual cage for 7 days after the operation. Blood was collected from the jugular vein as required, and no restraints, such as tubes, were used. On day 7, the animals were sufficiently anesthetized and sacrificed by exsanguination, which led to cardiac arrest. Their kidney was then removed, cut along the long axis and immersed in 10% formalin for pathological evaluation.

Measurement of 5-ALA concentrations in blood

Blood was sampled 1.5 h after 5-ALA administration on day 0, and serum concentrations of 5-ALA were measured according to the previously reported method, with some modifications [13]. Approximately 40 µL of 25% trichloroacetic acid solution was added to 100 µL of serum; the solution was mixed and centrifuged, and 10 µL of supernatant was collected. Subsequently, the 10 µL of supernatant, 240 µL of MilliQ water, 250 µL of 0.2 M acetate buffer (pH 3.8), and 1.25 mL of solution A (400 mg sodium chloride) were dissolved in 75 mL of MilliQ water. Thereafter, 10 mL of ethanol and 15 mL of acetylatedone were added and mixed well. A sample solution of 250 µL of solution B was prepared, i.e., 4.5 mL of formalin was added to an appropriate amount of MilliQ water and diluted to 50 mL with MilliQ water. This sample solution was heated in boiling water for 15 min and immediately cooled in ice water. The reaction mixture was next applied to a high-performance liquid chromatography system (Nexera X2 system, RF-20A Xs fluorescence detector (Shimadzu) and a ZORBAX Eclipse Plus C18 Rapid Resolution High Throughput column (1.8 µm, 4.6 × 50 mm, Agilent) at 40 °C). The sample injection volume was 20 µL, the mobile phase was a 2.5% acetic acid-methanol mixture (6/4, v/v), and the flow rate was 1.0 mL/min.

Pathological evaluation of renal ischemia

Pathological changes in the kidney excised on day 7 were scored on the basis of the evaluation criteria used in previous mouse models [4]. For histopathological examination, coronal sections were cut, fixed with 10% formaldehyde and embedded in paraffin. A 5-µm section was prepared and stained with hematoxylin and eosin. Five fields of view each of the cortex and medulla (including the corticomedullary junction; total of 10 fields) were randomly imaged under a magnification of 200 ×. The incidence rate of renal disorders, including tubular degeneration (such as tubular necrosis), disappearance of the brush border of the proximal tubules, and tubule dilation, was scored as follows: 0–5%, 0; 5–10%, 1; 11–25%, 2; 26–45%, 3; 46–75%, 4; and 75–100%, 5. The scoring was evaluated by two different pathologists in a blinded manner.

Calculation of the HED

We calculated the approximate expression of the histopathological score (y, a dose-dependent parameter in the pharmacological evaluation of micro miniature pigs) and the approximate expression of 5-ALA (x) in blood 1.5 h after administration of 5-ALA with the following equation: y = -0.128 ln(x) + 4.2958 (1). Furthermore, when we plotted the 5-ALA dose (a) and 5-ALA levels in blood (b) 1 h after administration in humans, using data from a phase 1 study, we approximated the following function: b = f(a) …(2) (unpublished data). Here, we considered the blood 5-ALA concentration 1 h after administration in humans to be that at 1.5 h after administration in the micro miniature pigs; in other words, x = b. By deriving the inverse functions of equations (1) and (2), the HED (a) could be calculated from the histopathological score (y) via x and b. For example, if y = 4, a = 1.6 mg/kg, and if y = 3.7, a = 13.4 mg/kg.

Statistics

We used the score in each group to conduct a one-way analysis
of variance (one-way ANOVA) and Dunnett’s multiple comparison test on the control, 10 mg/kg 5-ALA, and 100 mg/kg 5-ALA groups. The significance level of these tests was 5%.

Results

No animal showed abnormalities under general conditions throughout the study period.

Pathological changes in the kidney after renal ischemia

The histopathological scores of the kidneys are shown in Table 1. In the control group, in the renal proximal tubule epithelial cells at the corticomedullary junction and just below the capsule we observed moderate levels of necrosis due to pyknosis and cytolysis. Furthermore, the proximal tubules without necrosis showed a slight misalignment of cell nuclei, a mild loss of brush border, and a mild-to-moderate dilation of the lumen from the distal renal tubules to the collecting duct. Compared with the controls, the total mean area in which proximal tubular cells underwent necrosis tended to be smaller in the 10 mg/kg 5-ALA group and was significantly smaller in the 100 mg/kg 5-ALA group (Fig. 2). Based on these observations, the histopathological score was 4.7 for the control group, 4.3 for the 10 mg/kg 5-ALA group, and 3.6 for the 100 mg/kg 5-ALA group (Table 1). The one-way ANOV A and Dunnett’s multiple comparison test showed that the values were significantly lower in both 5-ALA groups than in the controls (P < 0.05; Fig. 3a).

In all animals of the three groups, renal tubule degeneration with congestion was observed in multiple lesions, mainly in the intramedullary zone. The level of change was greatest in the control group, followed by the 10 mg/kg 5-ALA group and 100 mg/kg 5-ALA group. Macrophage and lymphocyte infiltration into the interstitium and tubules did not differ significantly between the three groups, although the control group showed a trend for more inflammatory cells. The serum concentrations of 5-ALA were negatively correlated with the histopathological scores (R² = 0.7551) (Fig. 3b).

Human equivalent dose

We estimated that doses of approximately 1.6 mg/kg and 13.4 mg/kg were required to obtain the histopathology scores of 4 and 3.7 in humans, respectively (Fig. 4).

Discussion

5-ALA has long been considered a functional amino acid in animals and plants and has been used in photodynamic therapy for human diseases, particularly cancer [3, 14]. 5-ALA is multifunctional and has multiple targets, and its effects differ depending on its concentration; consequently, the optimal dose is assumed to vary for each indication. ALA has only been tested...
in rodents to date, and these studies did not measure pharmacokinetics associated with pharmacodynamics. In vitro studies assumed that 5-ALA absorption levels are different in rodents, pigs, and humans and that human intestinal cells absorb only 8% of the administered 5-ALA [15]. This difference makes it difficult to predict clinical doses for humans on the basis of in vivo rodent findings. A phase 1 study of the pharmacokinetics of oral 5-ALA showed that the peak serum concentration occurred 1 to 2 h after administration of 50 mg to 1,500 mg (unpublished data).

Rodents are known to generally rapidly metabolize drugs, and the effective dose of drugs in rodents differs greatly from that in humans. On the other hand, the metabolism of pigs is closer to that of humans than rodents. Therefore, evaluating drug metabolism in pigs allows clinical doses in humans to be predicted more accurately. However, domestic pigs grow rapidly, so it is difficult to match their age with humans. Micro miniature pigs are more useful for such studies because they grow more slowly and have a low body weight, which allows experiments to be performed with lower doses of test drugs [9, 16]. Therefore, in this study we used micro miniature pigs as a renal ischemia-reperfusion injury model to more accurately determine the effective HED and blood concentration of 5-ALA by comparing the pharmacokinetic data on 5-ALA with those in humans.

This is the first report to demonstrate that the clinically

![Figure 2](image1.png)

**Figure 2.** Pathological evaluation of renal ischemia from five fields of view each of the cortex and medulla (including the corticomedullary junction), for a total of 10 fields. The fields of view were imaged randomly under a magnification of 200 × and scored according to the incidence rate of pathological changes, as described in the main text.

![Figure 3](image2.png)

**Figure 3.** (a) Values represent the mean histopathological scores ± SD for nine aspects in each group. One-way analysis of variance revealed a statistically significant difference (P < 0.001). *Indicates significant difference vs. control in Dunnett’s multiple comparison test (P < 0.05). (b) Correlation between histopathological scores and serum 5-ALA concentration. SD: standard deviation; ALA: aminolevulinic acid.
The effective dose of 5-ALA for humans can be predicted from experiments in animals. The study used micro miniature pigs to verify the inhibitory effect of 5-ALA on renal ischemia-reperfusion injury, which had been proven previously in smaller animals. It also analyzed the efficacy and pharmacokinetics of 5-ALA in each individual animal.

A limitation of the study is that 5-ALA is pharmacologically active on various heme-binding proteins, so the concentration of 5-ALA required for a specific pharmacological activity may differ depending on the desired effect.

The methods used in this study can be used in future studies to estimate the clinically effective dose of 5-ALA in humans by first determining the concentration in an animal model.

Acknowledgments

This study was conducted according to the recommendations of Motowo Nakajima and Tohru Tanaka (SBI Pharmaceuticals Co., Ltd., Tokyo, Japan). Furthermore, blood concentrations of 5-ALA were measured by Masato Usami (Neophama Japan Co., Ltd., Tokyo, Japan). We would like to express our sincere gratitude to them.

Financial Disclosure

The study was supported by a research grant from Neopharma Japan Co., Ltd.

Conflict of Interest

KF is an employee of Neopharma Japan Co., Ltd., and a visiting researcher at Keio University. The remaining authors have no conflicts of interest to declare.

Informed Consent

Not applicable.

Author Contributions

EK designed and performed the study. KF, YK, EK, and MS drafted the manuscript and did critical editing. KF and EK assisted and supported in sample collection and subsequent analysis with statistics. YK and KS carefully supervised this manuscript preparation and writing.

Data Availability

The data supporting the findings of this study are available from the corresponding author upon reasonable request.

References